SolventumSOLVEarnings & Financial Report
Solventum Corporation is an American health care company that was spun off from 3M on April 1, 2024.
SOLV Q3 2025 Key Financial Metrics
Revenue
$2.1B
Gross Profit
$1.1B
Operating Profit
$1.7B
Net Profit
$1.3B
Gross Margin
54.2%
Operating Margin
80.6%
Net Margin
60.4%
YoY Growth
0.7%
EPS
$7.22
Financial Flow
Solventum Q3 2025 Financial Summary
Solventum reported revenue of $2.1B for Q3 2025, with a net profit of $1.3B (60.4% margin). Cost of goods sold was $961.0M, operating expenses totaled $-555.0M.
Key Financial Metrics
| Total Revenue | $2.1B |
|---|---|
| Net Profit | $1.3B |
| Gross Margin | 54.2% |
| Operating Margin | 80.6% |
| Report Period | Q3 2025 |
Solventum Annual Revenue by Year
Solventum annual revenue history includes year-by-year totals (for example, 2024 revenue was $8.3B).
| Year | Annual Revenue |
|---|---|
| 2024 | $8.3B |
| 2023 | $8.2B |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.04B | $2.02B | $2.08B | $2.08B | $2.08B | $2.07B | $2.16B | $2.10B |
| YoY Growth | N/A | 0.2% | 0.2% | 0.4% | 1.9% | 2.7% | 3.8% | 0.7% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $13.94B | $14.71B | $14.58B | $14.74B | $14.46B | $14.53B | $15.07B | $13.97B |
| Liabilities | $2.28B | $10.86B | $11.71B | $11.55B | $11.50B | $11.27B | $11.43B | $8.99B |
| Equity | $11.67B | $3.85B | $2.87B | $3.19B | $2.96B | $3.26B | $3.65B | $4.99B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $442.0M | $355.0M | $169.0M | $219.0M | $29.0M | $169.0M | $76.0M |
Other Health Care Companies
ABT
Abbott Laboratories
Revenue
$11.4B
Net Profit
$1.6B
ABBV
AbbVie
Revenue
$15.8B
Net Profit
$186.0M
A
Agilent Technologies
Revenue
$1.9B
Net Profit
$434.0M
ALGN
Align Technology
Revenue
$995.7M
Net Profit
$56.8M
AMGN
Amgen
Revenue
$9.9B
Net Profit
$1.3B
BAX
Baxter International
Revenue
$3.0B
Net Profit
$-1.1B
BDX
Becton Dickinson
Revenue
$5.3B
Net Profit
$382.0M
TECH
Bio-Techne
Revenue
$295.9M
Net Profit
$38.0M
BIIB
Biogen
Revenue
$2.3B
Net Profit
$-48.9M
BSX
Boston Scientific
Revenue
$5.3B
Net Profit
$670.0M